Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C).
+ 1 more risk
Slightly overvalued with limited growth.
Share Price & News
How has Esperion Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ESPR's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: ESPR underperformed the US Biotechs industry which returned 28.5% over the past year.
Return vs Market: ESPR exceeded the US Market which returned 6.7% over the past year.
Price Volatility Vs. Market
How volatile is Esperion Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StIs Esperion Therapeutics, Inc.'s (NASDAQ:ESPR) CEO Being Overpaid?
2 months ago | Simply Wall StRainbows and Unicorns: Esperion Therapeutics, Inc. (NASDAQ:ESPR) Analysts Just Became A Lot More Optimistic
2 months ago | Simply Wall StEarnings Update: Esperion Therapeutics, Inc. (NASDAQ:ESPR) Just Reported And Analysts Are Boosting Their Estimates
Is Esperion Therapeutics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ESPR ($51.04) is trading below our estimate of fair value ($144.35)
Significantly Below Fair Value: ESPR is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ESPR is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: ESPR is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ESPR's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ESPR has negative assets, so we can't compare its PB Ratio to the US Biotechs industry average.
How is Esperion Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ESPR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ESPR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ESPR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ESPR's revenue (28.9% per year) is forecast to grow faster than the US market (9.4% per year).
High Growth Revenue: ESPR's revenue (28.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ESPR's Return on Equity is forecast to be high in 3 years time
How has Esperion Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ESPR is currently unprofitable.
Growing Profit Margin: ESPR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ESPR is unprofitable, and losses have increased over the past 5 years at a rate of -24.1% per year.
Accelerating Growth: Unable to compare ESPR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ESPR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).
Return on Equity
High ROE: ESPR's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is Esperion Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: ESPR has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: ESPR has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: ESPR has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: ESPR's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ESPR has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ESPR has less than a year of cash runway if free cash flow continues to reduce at historical rates of 24.8% each year
What is Esperion Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ESPR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ESPR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ESPR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ESPR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ESPR's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Tim Mayleben (59yo)
Mr. Timothy M. Mayleben, also known as Tim, M.B.A., has been the Chief Executive Officer and President of Esperion Therapeutics, Inc. since December 2012. Mr. Mayleben serves as an Advisor to several biote ...
CEO Compensation Analysis
Compensation vs Market: Tim's total compensation ($USD1.08M) is below average for companies of similar size in the US market ($USD4.72M).
Compensation vs Earnings: Tim's compensation has been consistent with company performance over the past year.
|CFO & Corporate Secretary||2.5yrs||US$485.50k||0.040% $566.1k|
|Chief Commercial Officer||2.25yrs||US$624.39k||0.032% $446.6k|
|Chief Technical Operations Officer||0.83yr||no data||no data|
|Senior Director of Investor Relations||2.17yrs||no data||no data|
|Chief Ethics & Compliance Officer||1yr||no data||no data|
|Vice President of Corporate Development & Strategy||no data||no data||no data|
|Head of Marketing||no data||no data||no data|
|Chief Development Officer||2.25yrs||no data||0.036% $510.4k|
|Senior Vice President of Clinical Development||2.25yrs||no data||no data|
Experienced Management: ESPR's management team is considered experienced (2.3 years average tenure).
|Independent Director||7.67yrs||US$300.00k||0.018% $253.6k|
|Lead Independent Director||4.58yrs||US$327.50k||0.048% $678.2k|
|Independent Non-Employee Director||0.33yr||no data||0.047% $657.3k|
|Independent Director||6.5yrs||US$295.00k||0.040% $565.1k|
|Independent Director||2.17yrs||US$308.39k||0.040% $565.1k|
|Independent Director||1.17yrs||US$513.36k||0.058% $818.7k|
|Independent Director||6.42yrs||US$295.00k||0.058% $820.4k|
Experienced Board: ESPR's board of directors are considered experienced (4.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.6%.
Esperion Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Esperion Therapeutics, Inc.
- Ticker: ESPR
- Exchange: NasdaqGM
- Founded: 2008
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.410b
- Shares outstanding: 27.62m
- Website: https://www.esperion.com
Number of Employees
- Esperion Therapeutics, Inc.
- 3891 Ranchero Drive
- Suite 150
- Ann Arbor
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ESPR||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Jun 2013|
|0ET||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jun 2013|
|0IIM||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Jun 2013|
Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination tablet, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/07/11 23:58|
|End of Day Share Price||2020/07/10 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.